JP2014521675A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521675A5
JP2014521675A5 JP2014523289A JP2014523289A JP2014521675A5 JP 2014521675 A5 JP2014521675 A5 JP 2014521675A5 JP 2014523289 A JP2014523289 A JP 2014523289A JP 2014523289 A JP2014523289 A JP 2014523289A JP 2014521675 A5 JP2014521675 A5 JP 2014521675A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
biotinylated
group
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014523289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521675A (ja
JP6019118B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/064576 external-priority patent/WO2013017494A1/en
Publication of JP2014521675A publication Critical patent/JP2014521675A/ja
Publication of JP2014521675A5 publication Critical patent/JP2014521675A5/ja
Application granted granted Critical
Publication of JP6019118B2 publication Critical patent/JP6019118B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014523289A 2011-08-02 2012-07-25 吸入に適した酸化型アビジンの医薬品組成物 Active JP6019118B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11006338 2011-08-02
EP11006338.5 2011-08-02
PCT/EP2012/064576 WO2013017494A1 (en) 2011-08-02 2012-07-25 Pharmaceutical composition of oxidised avidin suitable for inhalation

Publications (3)

Publication Number Publication Date
JP2014521675A JP2014521675A (ja) 2014-08-28
JP2014521675A5 true JP2014521675A5 (enExample) 2015-08-27
JP6019118B2 JP6019118B2 (ja) 2016-11-02

Family

ID=46581966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523289A Active JP6019118B2 (ja) 2011-08-02 2012-07-25 吸入に適した酸化型アビジンの医薬品組成物

Country Status (19)

Country Link
US (1) US9872831B2 (enExample)
EP (1) EP2739314B1 (enExample)
JP (1) JP6019118B2 (enExample)
KR (1) KR101966630B1 (enExample)
CN (1) CN103717239B (enExample)
AU (1) AU2012292229B2 (enExample)
BR (1) BR112014002593B1 (enExample)
CA (1) CA2842276C (enExample)
DK (1) DK2739314T3 (enExample)
EA (1) EA026453B1 (enExample)
ES (1) ES2729549T3 (enExample)
IL (1) IL230597A0 (enExample)
MX (1) MX355177B (enExample)
PH (1) PH12014500193A1 (enExample)
PL (1) PL2739314T3 (enExample)
PT (1) PT2739314T (enExample)
UA (1) UA114482C2 (enExample)
WO (1) WO2013017494A1 (enExample)
ZA (1) ZA201401921B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511747A (ja) 2013-01-04 2016-04-21 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子表面結合に基づく薬物の組織への送達
WO2017201436A1 (en) * 2016-05-19 2017-11-23 University Of Miami Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384128A (en) * 1993-03-02 1995-01-24 University Of Alabama Research Foundation Method of and compounds for treatment for cystic fibrosis
NZ271181A (en) 1993-07-19 1998-06-26 Amgen Inc Protein protection; method for stabilising aerosolised proteins by adding a water-soluble polar organic compound to the aqueous solution prior to aerosolisation
NZ337924A (en) * 1997-02-20 2002-09-27 Klaus Kimmeldirk Site-specific drug delivery compounds comprising an anchoring moiety, a linking group and a drug
AU779869B2 (en) * 1999-04-13 2005-02-17 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
ITRM20030196A1 (it) * 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento
EP2311793A1 (en) * 2004-12-17 2011-04-20 Cipla Ltd. Crystalline levosalbutamol sulphate (Form II)
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
MX2010001302A (es) 2007-08-02 2010-03-01 Sigma Tau Ind Farmaceuti Avidina oxidada con tiempo de residencia elevado en tejidos tratados.
EP2106806A1 (en) * 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof

Similar Documents

Publication Publication Date Title
US11878977B2 (en) JAK inhibitors containing a 4-membered heterocyclic amide
Vandercappellen et al. The role of CXC chemokines and their receptors in cancer
ES2391087T3 (es) Anticuerpos de IL-9 recombinantes y usos de los mismos
EP3837258B1 (en) Dimethyl amino azetidine amides as jak inhibitors
JP4598517B2 (ja) 安定化した抗rsv抗体液体製剤
HRP20210650T1 (hr) Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
JP2011173911A5 (enExample)
JP2018009002A5 (enExample)
JP2009536170A (ja) 治療用の抗体標的指向サイトカイン
EP1623011A2 (en) IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
JP2013121353A5 (enExample)
JP2016508143A5 (enExample)
HRP20151352T1 (hr) Antagonisti toll-sliäśnih receptora 3
Merolla et al. Respiratory syncytial virus replication in human lung epithelial cells: inhibition by tumor necrosis factor alpha and interferon beta
JP2010538619A5 (enExample)
JP2021504321A5 (enExample)
Thipphawong Inhaled cytokines and cytokine antagonists
US20230201208A1 (en) Composition and methods for treating respiratory diseases
JP2012526800A (ja) 炎症性呼吸器疾患の治療または予防のための呼吸器内投与用薬学製剤および前記疾患の治療または予防方法
ES2729549T3 (es) Composición farmacéutica de avidina oxidada adecuada para la inhalación
JP2023553117A5 (enExample)
Cebalo et al. Chemokine production predominates in human monocytes infected with Tula virus
JP2011512120A5 (enExample)
Lee et al. Comparison of Cytokine Expressions among Kawasaki Disease and Its Symptom-related Diseases
CN117467006A (zh) 一种抗tslp抗体及其制剂与应用